(Q38852256)

7 September 2017

1 reference

title

Combinatorial approach to cancer immunotherapy: strength in numbers (English)

1 reference

7 September 2017

1 reference

3

Ann Richmond

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

15 May 2020

author name string

Anna E Vilgelm

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

15 May 2020

Douglas B Johnson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

15 May 2020

publication date

2 June 2016

1 reference

Journal of Leukocyte Biology

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

15 May 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

15 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

15 May 2020

page(s)

275-290

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

15 May 2020

cites work

1 reference

12 December 2020

Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation

1 reference

12 December 2020

Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40.

1 reference

12 December 2020

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 December 2020

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors

1 reference

12 December 2020

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

1 reference

12 December 2020

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

1 reference

12 December 2020

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

1 reference

12 December 2020

CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor

1 reference

12 December 2020

T-cell regulation by CD28 and CTLA-4.

1 reference

12 December 2020

Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134).

1 reference

12 December 2020

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

12 December 2020

5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.

1 reference

12 December 2020

Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.

1 reference

12 December 2020

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

12 December 2020

Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells

1 reference

12 December 2020

T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma

1 reference

12 December 2020

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.

1 reference

12 December 2020

Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo

1 reference

12 December 2020

B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse

1 reference

12 December 2020

Role of LAG-3 in regulatory T cells.

1 reference

12 December 2020

Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer

1 reference

12 December 2020

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

1 reference

12 December 2020

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

1 reference

12 December 2020

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

1 reference

12 December 2020

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

1 reference

12 December 2020

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

1 reference

12 December 2020

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

1 reference

12 December 2020

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

12 December 2020

LAG-3, a novel lymphocyte activation gene closely related to CD4

1 reference

12 December 2020

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

1 reference

12 December 2020

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

1 reference

12 December 2020

Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice

1 reference

12 December 2020

Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.

1 reference

12 December 2020

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

1 reference

12 December 2020

Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors

1 reference

12 December 2020

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

1 reference

12 December 2020

The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer

1 reference

12 December 2020

Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

1 reference

12 December 2020

CTLA-4 control over Foxp3+ regulatory T cell function

1 reference

12 December 2020

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

1 reference

12 December 2020

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

1 reference

12 December 2020

Senescence-messaging secretome: SMS-ing cellular stress

1 reference

12 December 2020

CD28 and CTLA-4 coreceptor expression and signal transduction

1 reference

12 December 2020

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

1 reference

12 December 2020

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

1 reference

12 December 2020

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

12 December 2020

The senescence-associated secretory phenotype: the dark side of tumor suppression

1 reference

12 December 2020

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

12 December 2020

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

12 December 2020

Circulating mitochondrial DAMPs cause inflammatory responses to injury

1 reference

12 December 2020

The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro

1 reference

12 December 2020

Control of immunity by the TNFR-related molecule OX40 (CD134)

1 reference

12 December 2020

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

1 reference

12 December 2020

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

1 reference

12 December 2020

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

1 reference

12 December 2020

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

1 reference

12 December 2020

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

1 reference

12 December 2020

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

1 reference

12 December 2020

Therapy-induced senescence in cancer

1 reference

12 December 2020

TIM-3: a novel regulatory molecule of alloimmune activation.

1 reference

12 December 2020

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

1 reference

12 December 2020

4-1BB signaling beyond T cells

1 reference

12 December 2020

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

1 reference

12 December 2020

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors

1 reference

12 December 2020

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.

1 reference

12 December 2020

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

1 reference

12 December 2020

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

1 reference

12 December 2020

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

12 December 2020

Combining immunotherapy and targeted therapies in cancer treatment

1 reference

12 December 2020

Immune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologies

1 reference

12 December 2020

Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection

1 reference

12 December 2020

Abscopal effect in a patient with melanoma

1 reference

12 December 2020

CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

1 reference

12 December 2020

Immunogenic cell death and DAMPs in cancer therapy

1 reference

12 December 2020

Immunogenic cell death in cancer therapy

1 reference

12 December 2020

Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.

1 reference

12 December 2020

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

12 December 2020

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas

1 reference

12 December 2020

Molecular mechanisms of T cell co-stimulation and co-inhibition

1 reference

12 December 2020

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma

1 reference

12 December 2020

Hepatotoxicity with combination of vemurafenib and ipilimumab

1 reference

12 December 2020

Danger signalling during cancer cell death: origins, plasticity and regulation.

1 reference

12 December 2020

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 December 2020

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

1 reference

12 December 2020

TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

1 reference

12 December 2020

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

12 December 2020

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer

1 reference

12 December 2020

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

1 reference

12 December 2020

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

1 reference

12 December 2020

OX40 is a potent immune-stimulating target in late-stage cancer patients

1 reference

12 December 2020

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

1 reference

12 December 2020

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

1 reference

12 December 2020

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

1 reference

12 December 2020

PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer

1 reference

12 December 2020

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

1 reference

12 December 2020

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

1 reference

12 December 2020

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity

1 reference

12 December 2020

Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.

1 reference

12 December 2020

Tim-3: an emerging target in the cancer immunotherapy landscape

1 reference

12 December 2020

Therapeutic vaccines for cancer: an overview of clinical trials

1 reference

12 December 2020

Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer

1 reference

12 December 2020

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

1 reference

12 December 2020

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

1 reference

12 December 2020

Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death

1 reference

12 December 2020

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

1 reference

12 December 2020

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

12 December 2020

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

1 reference

12 December 2020

Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo

1 reference

12 December 2020

Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.

1 reference

12 December 2020

Universes collide: combining immunotherapy with targeted therapy for cancer

1 reference

12 December 2020

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

12 December 2020

OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

12 December 2020

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 December 2020

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

12 December 2020

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

1 reference

12 December 2020

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

1 reference

12 December 2020

Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.

1 reference

12 December 2020

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

1 reference

12 December 2020

Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade

1 reference

12 December 2020

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

12 December 2020

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

12 December 2020

An unexpected journey: how cancer immunotherapy has paved the way for an HIV-1 cure

1 reference

12 December 2020

The future of immune checkpoint therapy

1 reference

12 December 2020

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients

1 reference

12 December 2020

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

12 December 2020

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

12 December 2020

Trial watch: IDO inhibitors in cancer therapy

1 reference

12 December 2020

Combinatorial strategies for the induction of immunogenic cell death

1 reference

12 December 2020

Epigenetics meets immune checkpoints.

1 reference

12 December 2020

Classifying Cancers Based on T-cell Infiltration and PD-L1.

1 reference

12 December 2020

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

1 reference

12 December 2020

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

1 reference

12 December 2020

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

12 December 2020

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models

1 reference

12 December 2020

Therapeutic Advances and Treatment Options in Metastatic Melanoma

1 reference

12 December 2020

CD70: An emerging target in cancer immunotherapy

1 reference

12 December 2020

Therapeutic cancer vaccines.

1 reference

12 December 2020

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.

1 reference

12 December 2020

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

1 reference

12 December 2020

Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists

1 reference

12 December 2020

Antagonists of PD-1 and PD-L1 in Cancer Treatment

1 reference

12 December 2020

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

1 reference

12 December 2020

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

12 December 2020

Emerging immune checkpoints for cancer therapy

1 reference

12 December 2020

Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses

1 reference

12 December 2020

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

1 reference

12 December 2020

Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models

1 reference

12 December 2020

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

12 December 2020

TIGIT predominantly regulates the immune response via regulatory T cells.

1 reference

12 December 2020

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

1 reference

12 December 2020

Checkpoint blockade in combination with cancer vaccines

1 reference

12 December 2020

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

1 reference

12 December 2020

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

1 reference

12 December 2020

Low dose cyclophosphamide: Mechanisms of T cell modulation

1 reference

12 December 2020

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

1 reference

12 December 2020

Rationale for anti-OX40 cancer immunotherapy

1 reference

12 December 2020

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment

1 reference

12 December 2020

The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies

1 reference

12 December 2020

Activation of human dendritic cells through CD40 cross-linking.

1 reference

12 December 2020

CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins

1 reference

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 December 2020

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

1 reference

12 December 2020

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

12 December 2020

A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis

1 reference

12 December 2020

Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers

1 reference

12 December 2020

CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase

1 reference

12 December 2020

Prevention of allogeneic fetal rejection by tryptophan catabolism

1 reference

12 December 2020

10.1189/JLB.5RI0116-013RR

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

15 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6608090&resulttype=core&format=json

15 May 2020

1 reference